In 2015, reported funding for HIV prevention R&D decreased from US$1.26 billion in 2014 to US$1.18 billion. However, overall funding has remained essentially flat for over a decade. For more on the state of funding in 2015, download our two-page update below.
The Resource Tracking for HIV Prevention R&D Working Group (RTWG), led by AVAC, in partnership with the International AIDS Vaccine Initiative and UNAIDS tracks trends in R&D investments and expenditures for biomedical HIV prevention options, including AIDS vaccines, microbicides, multipurpose prevention technologies, pre-exposure prophylaxis (PrEP), treatment as prevention, medical male circumcision, female condoms, HSV-2 vaccines, HIV cure and therapeutic vaccines.
Our last full report, HIV Prevention Research & Development Funding Trends 2000-2014, is available for download below. We will be releasing a new, updated report in October 2016.
The Working Group generates estimates of R&D investment that can be compared year to year across options and strategies and funding sources, helping assess the impact of public policies aimed at accelerating scientific progress and to provide facts for advocacy. This effort provides transparency for funders, policy makers and HIV/AIDS advocates so they can better understand and track investment flows.
(All 2015 are currently subject to change. Final figures will be available in our full report this October.)